KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

LifeMD (LFMD) EBIAT (2016 - 2025)

LifeMD filings provide 14 years of EBIAT readings, the most recent being $20.0 million for Q4 2025.

  • On a quarterly basis, EBIAT rose 397.74% to $20.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $17.0 million, a 173.94% increase, with the full-year FY2025 number at $14.4 million, up 161.94% from a year prior.
  • EBIAT hit $20.0 million in Q4 2025 for LifeMD, up from -$3.8 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $20.0 million in Q4 2025 to a low of -$18.0 million in Q4 2021.
  • Median EBIAT over the past 5 years was -$6.3 million (2023), compared with a mean of -$6.6 million.
  • Biggest five-year swings in EBIAT: crashed 393.98% in 2021 and later surged 397.74% in 2025.
  • LifeMD's EBIAT stood at -$18.0 million in 2021, then skyrocketed by 33.72% to -$11.9 million in 2022, then soared by 68.73% to -$3.7 million in 2023, then tumbled by 79.66% to -$6.7 million in 2024, then surged by 397.74% to $20.0 million in 2025.
  • The last three reported values for EBIAT were $20.0 million (Q4 2025), -$3.8 million (Q3 2025), and -$1.1 million (Q2 2025) per Business Quant data.